Craft

Hansa Biopharma

Stock Price

KR37.9

2024-10-29

Market Capitalization

KR2.5 B

2024-10-29

Revenue

KR222.3 M

FY, 2025

Hansa Biopharma Summary

Company Summary

Overview
Hansa Biopharma (previously known as Hansa Medical) is a biopharmaceutical company developing immunomodulating therapies. It offers an enzyme technology platform that helps to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer.
Type
Public
Status
Active
Founded
2007
HQ
Lund, SE | view all locations
Website
https://hansabiopharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Max Sakajja

    Max Sakajja, Vice President, Corporate Strategy

  • Anne Säfström Lanner

    Anne Säfström Lanner, Senior Vice President, Chief Human Resources Officer

    • Søren Tulstrup

      Søren Tulstrup, President and Chief Executive Officer

      LocationsView all

      1 location detected

      • Lund, Skåne län HQ

        Sweden

        Scheelevägen 22

      Hansa Biopharma Financials

      Summary Financials

      Revenue (Q1, 2026)
      kr34.6M
      Gross profit (Q1, 2026)
      kr20.8M
      Net income (Q1, 2026)
      (kr196.3M)
      Cash (Q1, 2026)
      kr676.5M
      EBIT (Q1, 2026)
      (kr142.5M)
      Enterprise value
      $3.0B

      Footer menu